Latest:
Dr. Bhatt on the Investigation of Trastuzumab Deruxtecan in HER2-Low Breast Cancer
Ruchi Bhatt, DO, discusses the investigation of trastuzumab deruxtecan in HER2-low breast cancer.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Ismail Jatoi, MD
Latest:
Dr. Jatoi on SLN Biopsy in ER-Positive, HER2-Negative Breast Cancer
Ismail Jatoi, MD, discusses the importance of individualized care when deciding whether to omit sentinel lymph node biopsy in patients over the age of 70 with clinically node-negative, estrogen receptor–positive, HER2-negative breast cancer.
Irene Morae Kang, MD
Latest:
Dr. Kang on Key Results From the PALOMA-2 and PALOMA-3 Trials in Advanced Breast Cancer
Irene Morae Kang, MD, discusses key overall survival data from the phase 3 PALOMA-2 and PALOMA-3 trials, which evaluated the addition of palbociclib to standard endocrine therapy for patients with advanced breast cancer.
Linda Ahn, MSN, ANP-BC, AOCNP
Latest:
Looking Ahead: Unmet Needs and Future Directions in the Treatment of Advanced EGFR-Mutant NSCLC
Panelists discuss how despite recent advances in first-line treatments, unmet needs remain. These include better personalized care, community education, understanding resistance mechanisms, central nervous system (CNS) metastases management, and development of novel therapies such as antibody-drug conjugates.
Fiona Simpkins, MD
Fiona Simpkins, MD, is the Hilarie L. and Mitchell L. Morgan President’s Distinguished Professor in Women’s Health at the University of Pennsylvania Perelman School of Medicine in Philadelphia; an attending physician of Gynecologic Oncology in the Department of Ob/Gyn in the Hospital of the University of Pennsylvania; director of Clinical & Translational Gynecologic Oncology Research at the Penn Medicine Health System; and active staff of Gynecologic Oncology in the Department of Ob/Gyn at Chester County Hospital.
Latest:
Dr Simpkins on the Clinical Applicability of Cyclin E1 Protein Expression as a Biomarker for Response to Azenosertib in Ovarian Cancer
Fiona Simpkins, MD, discusses the utility of cyclin E1 protein expression as a biomarker to predict response to azenosertib in ovarian cancer.
Jose Javier Bravo-Cordero, MD
Latest:
Dr. Bravo-Cordero on the Role of the Extracellular Matrix in Breast Cancer Dormancy
Jose Javier Bravo-Cordero, MD, discusses the role of extracellular matrix proteomics and disseminating tumor cells when regulating the tumor microenvironment to induce dormancy in breast cancer.
Morana Vojnic, MD, MBA
Morana Vojnic, MD, MBA, is the director of neuro-oncology at Rutgers Cancer Institute and the system leader for neuro oncology at RWJBarnabas Health.
Latest:
Dr Vojnic on Vorasidenib in Grade 2 IDH1/2-Mutated Glioma
Morana Vojnic, MD, MBA, discusses vorasidenib in grade 2 IDH1/2-mutated glioma.
Ahmet Sezer, MD
Latest:
Dr. Sezer on the FDA Approval of Cemiplimab in Frontline Advanced NSCLC With High PD-L1 Expression
Ahmet Sezer, MD, professor, Department of Medical Oncology, Başkent University, Adana, Turkey, discusses the FDA approval of cemiplimab-rwlc (Libtayo) as frontline treatment for patients with advanced non–small cell lung cancer (NSCLC) and high PD-L1 expression.